Application of oncolytic adenovirus expressing bispecific antibody in combination with CART in tumor treatment

The invention belongs to the technical field of biological medicines, and particularly relates to application of oncolytic adenovirus expressing a bispecific antibody in combination with CART in tumor treatment. The invention provides combined application of three tumor immunotherapies of oncolytic adenovirus, a bispecific antibody and CART (chimeric antigen receptor T). The recombinant oncolytic adenovirus expresses and secretes MUC16-BiTE, and the MUC16-BiTE can bridge tumor cells and CART cells, induce immune synapse formation and stimulate CART cell activation; the recombinant oncolytic adenovirus can dissolve tumor cells, increase CART cell infiltration, generate a pro-inflammatory environment, promote solid tumor immune activation and overcome tumor immunosuppression. The MUC16-BiTE obtained after recombination can target a CART cell CD3 antigen and a tumor cell MUC16 antigen at the same time, the targeting performance of the CART is enhanced, meanwhile, adverse reactions caused by systemic administrati